Analysts expect that Kindred Biosciences Inc (NASDAQ:KIN) will report earnings of ($0.33) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Kindred Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.37) and the highest estimate coming in at ($0.29). Kindred Biosciences posted earnings per share of ($0.29) in the same quarter last year, which suggests a negative year over year growth rate of 13.8%. The firm is scheduled to report its next earnings results on Wednesday, March 7th.
On average, analysts expect that Kindred Biosciences will report full year earnings of ($1.19) per share for the current year, with EPS estimates ranging from ($1.24) to ($1.14). For the next fiscal year, analysts expect that the firm will post earnings of ($1.22) per share, with EPS estimates ranging from ($1.37) to ($1.09). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Kindred Biosciences.
Kindred Biosciences (NASDAQ:KIN) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04.
KIN has been the subject of a number of recent analyst reports. Zacks Investment Research cut Kindred Biosciences from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. HC Wainwright initiated coverage on Kindred Biosciences in a research report on Friday, November 17th. They set a “buy” rating and a $9.50 target price for the company. B. Riley reaffirmed a “buy” rating and set a $11.00 target price on shares of Kindred Biosciences in a research report on Monday, November 20th. Finally, ValuEngine raised Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, December 1st. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $9.63.
Shares of Kindred Biosciences (NASDAQ:KIN) traded up $0.10 during trading on Monday, reaching $8.15. The company’s stock had a trading volume of 126,806 shares, compared to its average volume of 142,351. Kindred Biosciences has a 52-week low of $4.15 and a 52-week high of $9.65.
Several institutional investors and hedge funds have recently bought and sold shares of KIN. General American Investors Co. Inc. bought a new stake in shares of Kindred Biosciences in the third quarter valued at approximately $5,232,000. AJO LP bought a new stake in shares of Kindred Biosciences in the second quarter valued at approximately $2,407,000. Vanguard Group Inc. boosted its position in shares of Kindred Biosciences by 57.7% in the second quarter. Vanguard Group Inc. now owns 745,322 shares of the biopharmaceutical company’s stock valued at $6,410,000 after acquiring an additional 272,612 shares during the period. State Street Corp bought a new stake in shares of Kindred Biosciences in the second quarter valued at approximately $2,209,000. Finally, Pacific Grove Capital LP bought a new stake in shares of Kindred Biosciences in the third quarter valued at approximately $1,475,000. 66.85% of the stock is owned by institutional investors.
About Kindred Biosciences
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.